Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,305 shares of the medical research company’s stock after buying an additional 425 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.4% of Kavar Capital Partners Group LLC’s investment portfolio, making the stock its 9th largest position. Kavar Capital Partners Group LLC’s holdings in Thermo Fisher Scientific were worth $14,582,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $25,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $30,000. Noble Wealth Management PBC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $35,000. Finally, Cassady Schiller Wealth Management LLC increased its stake in Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TMO shares. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 21st. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, Argus decreased their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $604.05.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $410.45 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The stock has a market capitalization of $154.94 billion, a PE ratio of 24.07, a PEG ratio of 2.13 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The stock has a 50-day simple moving average of $410.39 and a 200-day simple moving average of $485.33.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the firm earned $5.11 earnings per share. The firm’s quarterly revenue was up .2% on a year-over-year basis. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.